Vrbpac Meeting 2025. Kool Fool on Twitter "RT joaquinlife Dr. James Hildreth VRBPAC member, "I'm also concerned An FDA spokesperson said the agency would make its recommendations to manufacturers public in time for updated vaccines to be available for the 2025-26 influenza season The Committee reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products which are intended for use in the prevention.
Public Comment from Mitchell Warren, Executive Director, AVAC At the Vaccines and Related from avac.org
It comes as RFK Jr., a vaccine skeptic who now leads the Department of Health and Human Services, makes moves that could affect vaccination uptake and policy. The Committee reviews and evaluates data concerning the safety, effectiveness, and appropriate use of vaccines and related biological products which are intended for use in the prevention.
Public Comment from Mitchell Warren, Executive Director, AVAC At the Vaccines and Related
A March meeting of vaccine advisers to the US Food and Drug Administration to discuss flu shots for the 2025-26 season was cancelled. The CDC reports 33 million flu illnesses, 430,000 hospitalizations, and 19,000 deaths as of February 2025, with Influenza A(H1N1) and A(H3N2) as the primary strains. abruptly cancel the planned meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which is the annual opportunity for FDA to hear expert advice and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2025 to 2026 influenza season.
Sense Receptor on Twitter "13. William Gruber, SVP of Vaccine Clinical Research and Development. "A planned March 13 meeting of the FDA's Vaccines and Related Biological Products Advisory Committee on the influenza vaccine strains for the 2025-2026 influenza season in the northern. The FDA's Vaccines and Related Biological Products Advisory Committee had been scheduled to.
2025 Annual Meeting. abruptly cancel the planned meeting of the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which is the annual opportunity for FDA to hear expert advice and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2025 to 2026 influenza season. The FDA's VRBPAC meeting scheduled for March 13, 2025, to select flu strains for the 2025-2026 season has been canceled, which may delay flu vaccine production